CD4 and myeloid sarcoma: A representative plot of five subpopulations within CD4+ cells and CD4+CD25+CD127loTreg population is shown as Fig. 2A. To identify if changes demonstrated in studies of all MS patients (Fig. 2B–D), were a marker of immune changes intrinsic to MS or a consequence of immune modifying therapy, we compared CD4+ and CD4+CD25+CD127lo Treg from treatment naïve MS patients (n = 12) and HD (Fig. 2E–G).